Qualigen Therapeutics (QLGN) - Earnings growth in current year

Qualigen Therapeutics (QLGN) demonstrates high macro-resilience, as the development of cancer and viral drugs remains independent of economic cycles. Growth is driven by the implementation of the FastPack system and the progress of the QN-302 drug. The year-over-year earnings per share trend shows that the value is fixed at 0.00. However, the company is currently experiencing a technological stalemate with a limited set of preclinical studies.

QLGN Qualigen Therapeutics, Inc. Earnings per share growth in current year (07/04/2022 - 11/19/2025)

Financial and market metric breakdowns for qualigeninc.com (QLGN)

- stock price and consensus target price:

Price Performance Chart Qualigen Therapeutics|QLGN - Consensus Target

- market capitalization indicators:

Market Capitalization Qualigen Therapeutics, Inc.|QLGN - Total Company Value

- book capitalization data:

Net Assets per Share Qualigen Therapeutics|QLGN - Company Book Value|Market Value to Equity Ratio qualigeninc.com|QLGN - Cumulative Company Assets

- debt and liquidity details:

- earnings and multiples data:

QLGN - Net Profit|Expected Net Profit Qualigen Therapeutics|QLGN - Price to Earnings Ratio|Price to Future Earnings Ratio Qualigen Therapeutics, Inc.|QLGN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Qualigen Therapeutics Inc|QLGN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Qualigen Therapeutics|QLGN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months qualigeninc.com|QLGN - Earnings growth in current year|Expected net earnings per share growth next year Qualigen Therapeutics

- revenue and sales proceeds data:

QLGN - Company Revenue|Company Future Revenue Qualigen|QLGN - P/S Multiple|Forward P/S Multiple Qualigen Therapeutics, Inc.|QLGN - Sales Growth YoY (Last Twelve Months)

Basic company analysis:Qualigen, QLGN

Manufactured product of Qualigen Therapeutics

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety. This indicator captures the annual percentage change in EPS, reflecting real business efficiency and the impact of operating expenses on final profitability. In the case of Qualigen Therapeutics (QLGN), the annual EPS change range demonstrates how R&D outsourcing and reliance on external vendors affect the financial result.

Direct competitors